Ad is loading...
MENU

ENLV Stock Enlivex Therapeutics (ENLV, $0.84) price may climb as it broke lower Bollinger Band on Nov 21, 2024

A.I.dvisor
at Tickeron.com
Loading...
ENLV - Enlivex Therapeutics Ltd
Bollinger signal
Bullish Trend
Odds of UP Trend
Tickeron
Bollinger signal
Price: $0.841
Daily change: -$0.135 (-13.83%)
Daily volume: 422.5K
Industry: Biotechnology
This price move could be a signal that ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 38 similar cases where ENLV's price broke its lower Bollinger Band, and of them led to a successful outcome. Odds of Success:

ENLV's RSI Oscillator sits in oversold zone for 12 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ENLV as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ENLV turned negative on October 18, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

ENLV moved below its 50-day moving average on October 29, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ENLV crossed bearishly below the 50-day moving average on November 01, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ENLV entered a downward trend on November 22, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.696) is normal, around the industry mean (13.913). P/E Ratio (0.000) is within average values for comparable stocks, (89.373). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.810). ENLV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (226.220).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ENLV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
14 Einstein Street
Phone
+972 26208072
Employees
77
Web
https://www.enlivex.com